The CHS is currently developing the next CHS Strategic Plan. We would appreciate your insights into how we can further our mission and enhance our...
Please CLICK HERE to read a special message from CHS President, Emil Wijnker, and Chief Executive Officer, Sarah Ford.
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....
The Canadian Hemophilia Society is delighted to invite you to attend Rendez-vous 2025 coming up May 1-4, 2025, in Winnipeg. CLICK HERE for a glimpse at the...
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
PREAMBLE We have already come to the end of this important series of articles about the national board and operational committees on which our volunteers...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the International...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the latest...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the Finance...
My name is Andrea, and I am the mom to my son Nicklas, who has severe hemophilia A. I am writing today to share a...
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the Care...
For many years I coordinated the publication of articles written by participants who had attended the WFH World Congresses for the CHS newsmagazine, Hemophilia Today....
Montreal, July 5, 2024 – Canada’s two health technology assessment (HTA) agencies have made conflicting recommendations on two gene therapies for hemophilia B. Earlier in...